ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1567

Association of Blood Count Biomarkers and Clinical Features with Immune Related Adverse Events (irAEs) in Patients with Cancer Treated with Checkpoint Inhibitors (CPI)

Despina Michailidou1, Ali R Khaki2, Guangyu Wang3, Leonidas Diamantopoulos2 and Petros Grivas2, 1Division of Rheumatology, University of Washington, Seattle, Washington, Seattle, WA, 2Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, Seattle, WA, 3Department of Biostatistics, University of Washington, Seattle, Washington, Seattle, WA

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, Biomarkers, Cohort Study, immunology

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 9, 2020

Session Title: Immunological Complications of Therapy Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with cancer treated with CPI can develop irAEs. Since immune changes may impact blood counts and ratios, we hypothesized that those would be associated with irAEs. We also investigated the association between irAEs and personal or family history of autoimmune disease (AD), combination of CPI and/or history of chronic infection.

Methods: We performed a retrospective cohort study and identified patients with solid and hematologic malignancies who started CPI (anti-PD1/PDL1 and anti-CTLA-4) in 2018. We defined irAEs as both rheumatologic and non-rheumatologic. The association between irAEs, baseline absolute neutrophil (ANC), lymphocyte (ALC), monocyte count (AMC), neutrophil to lymphocyte (NLR), monocyte to lymphocyte (MLR), platelet to lymphocyte ratio (PLR), was assessed by logistic regression (LR) with robust standard errors adjusting for age, sex, smoking history, cancer type, ECOG performance status (PS), concomitant systemic therapy, personal or family history of AD and chronic infection. LR with robust standard errors was also used to examine the relationship between irAEs and personal or family history of AD, combination of CPI and chronic infection adjusting for age, sex, smoking history, cancer type, ECOG PS, and concomitant systemic therapy. After Bonferroni correction, alpha level was set to 0.005 for all statistical testing.

Results: A total of 193 patients were identified with median age 64 (range 23-92), 47% women; 49% with smoking history; 23% had lung cancer, 21% skin cancer, 56% other cancers; 19% received concomitant CPI and 32% other systemic therapy plus CPI. Rheumatologic irAEs were reported in 10%, and non-rheumatologic irAEs in 23% of patients. Association between irAEs, blood biomarkers and clinical features are described in Table. Development of irAEs was significantly associated with higher baseline ALC (OR: 2.43, 95%CI: 1.39-4.22, p=0.002) and lower baseline MLR (OR: 0.09, 95%CI: 0.02-0.42, p=0.002). Patients with pre-existing AD (OR: 5.14, 95%CI: 2.18-12.15, p< 0.001) were also more likely to experience irAEs during treatment with CPI.

Conclusion: In patients with cancer treated with CPI, irAE development was associated with higher baseline ALC, lower MLR and pre-existing history of AD. Further validation is required to test our generated hypothesis that blood count subsets could be used as inexpensive and easily obtained biomarkers to predict the development of irAEs in clinical practice.


Disclosure: D. Michailidou, None; A. Khaki, Merck & Co, Inc., 1, Sanofi S. A., 1; G. Wang, None; L. Diamantopoulos, None; P. Grivas, AstraZeneca, 1, Bayer, 1, EMDSerono, 1, Exelixis, 1, Genzyme, 1, GlaxoSmithKline, 1, Janssen, 1, Merck, 1, 2, Mirati Therapeutics, 1, Pfizer, 1, 2, Roche, 1, Seattle Genetics, 1, Bavarian Nordic, 1, Bristol Myers Squibb, 1, Clovis Oncology, 1, Debiopharm, 1, Immunomedics, 1, QED Therapeutics, 1, 2.

To cite this abstract in AMA style:

Michailidou D, Khaki A, Wang G, Diamantopoulos L, Grivas P. Association of Blood Count Biomarkers and Clinical Features with Immune Related Adverse Events (irAEs) in Patients with Cancer Treated with Checkpoint Inhibitors (CPI) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/association-of-blood-count-biomarkers-and-clinical-features-with-immune-related-adverse-events-iraes-in-patients-with-cancer-treated-with-checkpoint-inhibitors-cpi/. Accessed January 22, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-blood-count-biomarkers-and-clinical-features-with-immune-related-adverse-events-iraes-in-patients-with-cancer-treated-with-checkpoint-inhibitors-cpi/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.